‘Always new twists’: Bayer legal team on defending a $4bn drug
With billions in revenue at stake, the pharma giant has a 27-country parallel litigation effort to protect its blockbuster blood thinner from generics. Marisa Woutersen finds Bayer’s outside litigation counsel ready for anything.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com
8 July 2026 UPC judges revoke a patent asserted against the companies over their Comirnaty COVID-19 vaccine, in a ruling that clarified the court’s key principles on exclusive licences, novelty and inventive step.
6 July 2026 The Unified Patent Court delivers a mixed ruling in a dispute over liquid biopsy technology, overturning a finding that a patent was likely invalid while refusing to grant interim relief because of the patent owner’s delay.
25 June 2026 A UK judge extends a blocking order aimed at ISPs including BT, EE, and Sky, allowing the maker of Ozempic and Wegovy to add infringing sites that sell counterfeits without returning to court.